Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JAGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company faces immediate delisting risk without grace period if stock falls below $1.00 for 30 days during one-year monitoring period.
Jaguar Health regains Nasdaq compliance but faces strict one-year monitoring with no grace period
Filed May 27, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Company regained compliance with Nasdaq's $1.00 minimum bid price requirement on May 26, 2026, after receiving a Decision Letter from the Nasdaq Hearings Panel following an appeal process.
Item 8.01 verify on EDGAR → -
high
Nasdaq imposed a mandatory one-year monitoring period through May 26, 2027, during which the Panel will maintain heightened oversight of the company's listing status through September 1, 2026.
Item 8.01 verify on EDGAR → -
high
If the stock trades below $1.00 for 30 consecutive business days during the monitoring period, Nasdaq will immediately issue a delisting determination without the standard 180-day grace period normally available.
Item 8.01 verify on EDGAR → -
medium
The company could request a new hearing before the Panel if a delisting determination is issued during the monitoring period, providing a potential avenue to contest removal from the exchange.
Item 8.01 verify on EDGAR →
Summary
Jaguar Health has successfully regained compliance with Nasdaq's minimum bid price requirement after an appeals process before the Nasdaq Hearings Panel. While this is positive news that avoids immediate delisting, the company now operates under significantly stricter conditions than typical listed companies.
The Panel has imposed a mandatory one-year monitoring period and eliminated the standard 180-day grace period that would normally apply if the stock falls below $1.00 again. For retail investors, this creates a precarious situation. The stock must maintain a closing bid price above $1.00 for at least 30 consecutive business days to avoid triggering an immediate delisting determination.
This is a much higher bar than companies face under normal circumstances, where they would receive six months to regain compliance. The heightened scrutiny reflects Nasdaq's concern about the company's ability to maintain listing standards. Investors should closely monitor the daily closing bid price over the coming months. Any sustained weakness that brings the stock near or below $1.00 could trigger rapid delisting proceedings. Watch for the September 1, 2026 date when the Panel's direct jurisdiction ends, and track whether the company can maintain price stability through the full May 26, 2027 monitoring period.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Jaguar Health disclosed a Decision Letter from the Nasdaq Hearings Panel via press release on May 27, 2026.
Added in current filing · verify on EDGAR →
On May 27, 2026, Jaguar Health, Inc. (the “Company”) issued a press release announcing the Decision Letter (as defined below) from the Nasdaq Hearings Panel, a copy of which is furnished as Exhibit 99.1.
The company disclosed receiving a Decision Letter from the Nasdaq Hearings Panel. A Hearings Panel is typically convened when a company appeals a Nasdaq staff delisting determination. The specific outcome of the decision is contained in the press release exhibit, not detailed in the 8-K body itself.
Event · Item 8.01 — Other Events
Jaguar Health regained Nasdaq compliance but faces one-year monitoring with no grace period if bid price falls below $1.00 again.
Added in current filing · verify on EDGAR →
On May 26, 2026, the Company was formally notified by Nasdaq that the Company had regained compliance with the Bid Price Rule (the “Compliance Determination”) but that the Panel would maintain jurisdiction over the Company and its listing until September 1, 2026, the outside date of the Panel’s discretion in this matter.
Jaguar Health regained compliance with Nasdaq's minimum $1.00 bid price requirement on May 26, 2026, after previously receiving extensions. However, the Nasdaq Hearings Panel will continue monitoring the company through September 1, 2026, indicating ongoing scrutiny of the listing status.
Added in current filing · verify on EDGAR →
The Compliance Determination further stated that, in accordance with Listing Rule 5815(d) (4) (B), the Company is subject to a Mandatory Panel Monitor for a period of one year from the date of the Compliance Determination, or May 26, 2027.
The company is now under a one-year mandatory monitoring period through May 26, 2027. This is a formal oversight mechanism imposed by Nasdaq on companies that have previously struggled with listing requirements, signaling heightened regulatory attention.
Event · Item 9.01 — Financial Statements and Exhibits
Jaguar Health filed an 8-K attaching a press release dated May 27, 2026, with no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release dated May 27, 2026.
The 8-K references an attached press release dated May 27, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content, making this a procedural filing. Investors should review Exhibit 99.1 directly to understand what was announced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify